Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s earnings release is expected by WallStreet on March, 7, according to RTT. This year’s EPS analyst estimate is expected to be $-0.21. That is 82.93 % up compareed to $-1.23 EPS for last year. Last quarter $-0.30 EPS was reported. Analysts sees -30.00 % EPS growth this quarter. TNDM hit $48.25 during the last trading session after $0.07 change.Currently Tandem Diabetes Care, Inc. is uptrending after 1365.83% change in last February 25, 2018. TNDM has also 824,686 shares volume. The stock outperformed the S&P 500 by 1365.83%.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Coverage

In total 5 analysts cover Tandem Diabetes Care (NASDAQ:TNDM). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. 80% are bullish. 7 are the (NASDAQ:TNDM)’s analyst reports since August 30, 2018 according to StockzIntelligence Inc. On Wednesday, November 21 the stock has “Outperform” rating by Robert W. Baird. On Friday, February 15 Robert W. Baird maintained Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rating. Robert W. Baird has “Buy” rating and $55 target. The company rating was downgraded by Robert W. Baird on Friday, September 14.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.The company has $2.77 billion market cap. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set.Last it reported negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

For more Tandem Diabetes Care, Inc. (NASDAQ:TNDM) news announced recently go to: Businesswire.com, Nasdaq.com, Seekingalpha.com, Seekingalpha.com or . The titles are as follows: “t:slim X2 Insulin Pump First to Receive New ACE Pump Classification by FDA – Business Wire” announced on February 14, 2019, “Is the Options Market Predicting a Spike in Tandem Diabetes (TNDM) Stock? – Nasdaq” on August 20, 2018, “Tandem Diabetes Care, Inc. (TNDM) CEO Kim Blickenstaff on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with a publish date: November 02, 2018, “Epic Rally In Tandem Diabetes Care, Can It Continue? – Seeking Alpha” and the last “Tandem Diabetes (TNDM) Q3 Earnings Preview: What to Look Out For – Yahoo Finance” with publication date: October 18, 2018.